Glaukos Reports 2017 Net Sales of $159.3 Million

March 9, 2018: By Joan McKenna

Glaukos reported Feb. 28 that 2017 net sales of its iStent implant totaled $159.3 million, a 39 percent increase over 2016 sales of $114.4 million.

Glaukos’ Q4-2017 net sales totaled $41.7 million, an increase of 26 percent year over year.

The San Clemente, California, company attributed the growth to unit volume increases worldwide, higher average selling prices, and expansion of the company’s direct sales operations to new international markets.

Glaukos launched the iStent, the first minimally invasive glaucoma surgery (MIGS) device, in 2012.

The device now faces growing competition, with other MIGS stents commercialized in late 2016 and 2017.

Glaukos provided net sales guidance for 2018 of $160 million to $165 million, the same range the firm initially provided for 2017.

In May 2017, Glaukos’ full-year guidance for 2017 was raised to $162 million to $167 million. In September 2017, the company lowered it to $155 million to $160 million.

Glaukos’ net loss in 2017 was $0.1 million compared with net income of $4.5 million in 2016.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023